Vimedimex Medi-Pharma JSC (HOSE:VMD)
Vietnam · Delayed Price · Currency is VND 14,250
-200 (-1.38%)
At close: Sep 23, 2026
Vimedimex Medi-Pharma JSC Financials Overview
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 399,898 | 812,983 | 1,249,868 | 3,536,651 | 7,073,499 | 12,318,752 |
Revenue Growth | -50.81% | -34.96% | -64.66% | -50.00% | -42.58% | -32.17% |
Gross Profit Gross Profit Growth | 93,985 | 82,316 | 118,944 | 279,256 | 544,766 | 1,068,687 |
Operating Income Operating Income Growth | 81,429 | 42,716 | 5,497 | 35,019 | 32,149 | 152,733 |
Net Income Net Income Growth | 62,706 | 42,361 | 22,016 | 25,482 | 34,818 | 19,995 |
Earnings Per Share EPS Growth | 4061.00 | 2743.54 | 1425.89 | 1650.00 | 2255.00 | 1295.00 |
EPS Growth | 48.02% | 92.41% | -13.58% | -26.83% | 74.13% | -46.10% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 396,824 | 353,542 | 335,082 | 249,455 | 256,375 | 179,911 |
Total Debt Total Debt Growth | - | - | - | - | - | 612,374 |
Net Cash (Debt) Net Cash Growth | 396,824 | 353,542 | 335,082 | 249,455 | 256,375 | -432,463 |
Net Cash Growth | 12.24% | 5.51% | 34.33% | -2.70% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 25700.56 | 22897.43 | 21701.83 | 16152.32 | 16604.34 | -28008.76 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -20,040 | 10,565 | 118,674 | 21,872 | 702,082 | -422,016 |
Capital Expenditures CapEx Growth | 1,490 | - | -7,001 | -16,329 | -5,163 | -20,468 |
Free Cash Flow Free Cash Flow Growth | -18,550 | 10,565 | 111,673 | 5,543 | 696,919 | -442,484 |
Free Cash Flow Growth | - | -90.54% | 1914.81% | -99.20% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 23.50% | 10.13% | 9.52% | 7.90% | 7.70% | 8.67% |
Operating Margin | 20.36% | 5.25% | 0.44% | 0.99% | 0.45% | 1.24% |
Pretax Margin | 22.67% | 6.61% | 2.45% | 1.13% | 0.67% | 0.23% |
Profit Margin | 15.68% | 5.21% | 1.76% | 0.72% | 0.49% | 0.16% |
FCF Margin | -4.64% | 1.30% | 8.94% | 0.16% | 9.85% | -3.59% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 2000.000 | - | - | - | - | - |
Dividend Per Share Growth | - | - | - | - | - | - |
Dividend Yield | 14.04% | - | - | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 3.51 | 6.01 | 11.57 | 10.30 | 9.27 | 27.41 |
P/FCF Ratio | - | 24.12 | 2.28 | 47.36 | 0.46 | - |
PS Ratio | 0.55 | 0.31 | 0.20 | 0.07 | 0.05 | 0.04 |